These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 19008458)
1. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458 [TBL] [Abstract][Full Text] [Related]
2. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299 [TBL] [Abstract][Full Text] [Related]
3. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374 [TBL] [Abstract][Full Text] [Related]
5. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Bates DJ; Danilov AV; Lowrey CH; Eastman A Mol Cancer Ther; 2013 Aug; 12(8):1504-14. PubMed ID: 23723123 [TBL] [Abstract][Full Text] [Related]
6. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401 [TBL] [Abstract][Full Text] [Related]
7. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia. Willimott S; Beck D; Ahearne MJ; Adams VC; Wagner SD Clin Cancer Res; 2013 Jun; 19(12):3212-23. PubMed ID: 23633452 [TBL] [Abstract][Full Text] [Related]
8. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. Soderquist R; Pletnev AA; Danilov AV; Eastman A Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590 [TBL] [Abstract][Full Text] [Related]
9. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
11. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980 [TBL] [Abstract][Full Text] [Related]
12. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Al-Harbi S; Hill BT; Mazumder S; Singh K; Devecchio J; Choudhary G; Rybicki LA; Kalaycio M; Maciejewski JP; Houghton JA; Almasan A Blood; 2011 Sep; 118(13):3579-90. PubMed ID: 21772052 [TBL] [Abstract][Full Text] [Related]
13. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698 [TBL] [Abstract][Full Text] [Related]
14. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609 [TBL] [Abstract][Full Text] [Related]
16. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063 [TBL] [Abstract][Full Text] [Related]
17. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
18. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL. Hari Y; Harashima N; Tajima Y; Harada M Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422 [TBL] [Abstract][Full Text] [Related]
19. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792 [TBL] [Abstract][Full Text] [Related]
20. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]